Market Cap 8.51M
Revenue (ttm) 2.79M
Net Income (ttm) 9.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 328.67%
Debt to Equity Ratio 0.00
Volume 102,000
Avg Vol 2,904,550
Day's Range N/A - N/A
Shares Out 10.16M
Stochastic %K 33%
Beta 1.45
Analysts Hold
Price Target $2.00

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also deve...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
Dwarn2021
Dwarn2021 Jun. 24 at 7:56 PM
$TRAW Interesting: https://srnnews.com/exclusive-trump-to-seek-more-than-1-4-billion-in-ebola-funding-from-congress/
1 · Reply
Boywithathorn
Boywithathorn Jun. 24 at 5:35 PM
$TRAW painful hold. Inept management. So what’s the deal with the fda hold on the influenza drug? Why not concentrate on getting that hold lifted rather than 2nd rate UK office? Though my average is 90 cents I’m not sure if these old facks have a clue at this company.
0 · Reply
Boywithathorn
Boywithathorn Jun. 23 at 9:56 PM
$TRAW good job shorts. Staying strong. We need you to bust though $1. It’s coming.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 23 at 8:32 PM
Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand https://ow.ly/Gc0Q50Zg1CJ Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors. $TRAW
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 23 at 4:18 PM
$TRAW 1 dollar incoming!!
0 · Reply
Boywithathorn
Boywithathorn Jun. 23 at 3:48 PM
$TRAW $TRAW wish it would flag and try to overtake $1.
0 · Reply
Jbjb90
Jbjb90 Jun. 23 at 2:21 PM
$TRAW starting to get more expensive to short again
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 22 at 8:25 PM
$TRAW shorts in trouble if they don't cover by end of the month, Q3 is only a few days away....
0 · Reply
Boywithathorn
Boywithathorn Jun. 22 at 7:50 PM
$TRAW Shorts are going to have to cover soon. Price will get back to normalcy. Prob $1.30-$1.50. They are not giving up on their drug but just putting together a better toxicology report. With doing so most likey will fix the issue. This keeps the 50 million warrants on base as well.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 22 at 7:38 PM
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program https://ow.ly/gzWJ50ZfpR8 Traws Pharma, Inc.'s ( $TRAW ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral.
0 · Reply
Latest News on TRAW
Traws Pharma provides update on tivoxavir marboxil program

2026-06-22T11:30:46.000Z - 3 days ago

Traws Pharma provides update on tivoxavir marboxil program


Traws Pharma downgraded to Neutral from Buy at Ladenburg

2026-06-15T10:52:38.000Z - 10 days ago

Traws Pharma downgraded to Neutral from Buy at Ladenburg


Traws Pharma Provides Regulatory Update on Influenza Program

Jun 12, 2026, 5:30 PM EDT - 12 days ago

Traws Pharma Provides Regulatory Update on Influenza Program


Traws Pharma Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 26 days ago

Traws Pharma Proxy statement: Proxy filing


Traws Pharma Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 26 days ago

Traws Pharma Proxy statement: Proxy filing


Traws Pharma Proxy statement: Proxy filing

May 19, 2026, 8:00 AM EDT - 5 weeks ago

Traws Pharma Proxy statement: Proxy filing


Traws Pharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Traws Pharma Quarterly report: Q1 2026


Traws Pharma Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Traws Pharma Earnings release: Q1 2026


Traws Pharma Registration statement: Registration filing

May 8, 2026, 8:00 AM EDT - 6 weeks ago

Traws Pharma Registration statement: Registration filing


Traws Pharma Earnings Call Transcript: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Earnings Call Transcript: Q4 2025


Traws Pharma Earnings release: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Earnings release: Q4 2025


Traws Pharma Annual report: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 2 months ago

Traws Pharma Annual report: Q4 2025


Traws Pharma initiated with a Buy at Ladenburg

2026-01-30T12:20:23.000Z - 5 months ago

Traws Pharma initiated with a Buy at Ladenburg


Traws Pharma initiated with a Buy at H.C. Wainwright

2025-12-03T11:10:09.000Z - 7 months ago

Traws Pharma initiated with a Buy at H.C. Wainwright


Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

2025-11-13T12:05:59.000Z - 7 months ago

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year


Traws Pharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Traws Pharma Quarterly report: Q3 2025


Traws Pharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Traws Pharma Earnings release: Q3 2025


Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma appoints John Leaman as independent director

2025-10-06T11:37:17.000Z - 9 months ago

Traws Pharma appoints John Leaman as independent director


Traws Pharma Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Earnings Call Transcript: Q2 2025


Traws Pharma Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Earnings release: Q2 2025


Traws Pharma Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Traws Pharma Quarterly report: Q2 2025


Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

2025-08-14T11:16:52.000Z - 11 months ago

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year


Traws Pharma announced multiple regulatory submissions

2025-06-30T10:44:40.000Z - 1 year ago

Traws Pharma announced multiple regulatory submissions


Traws Pharma Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Quarterly report: Q1 2025


Traws Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q1 2025


Traws Pharma Earnings Call Transcript: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q4 2024


Traws Pharma Annual report: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Annual report: Q4 2024


Traws Pharma Earnings release: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings release: Q4 2024


Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 1 year ago

Traws Pharma Announces Management Updates


Traws Pharma Proxy statement: Proxy Filing

Feb 6, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Registration statement: Registration Filing

Jan 15, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Registration statement: Registration Filing


Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data


Traws Pharma Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Quarterly report: Q3 2024


Traws Pharma Earnings release: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Traws Pharma Earnings release: Q3 2024


Traws Pharma Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings Call Transcript: Q2 2024


Traws Pharma Quarterly report: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q2 2024


Traws Pharma Earnings release: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q2 2024


Traws Pharma Proxy statement: Proxy Filing

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Proxy statement: Proxy Filing

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Registration statement: Registration Filing

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Registration statement: Registration Filing


Traws Pharma Proxy statement: Proxy Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Quarterly report: Q1 2024

May 16, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Quarterly report: Q1 2024


Traws Pharma Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Transcript: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Transcript: M&A Announcement


Traws Pharma Press release: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Press release: M&A Announcement


Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants


Traws Pharma Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Earnings release: Q4 2023


Traws Pharma Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Traws Pharma Annual report: Q4 2023


Traws Pharma Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Earnings Call Transcript: Q3 2023


Traws Pharma Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Quarterly report: Q3 2023


Traws Pharma Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Earnings release: Q3 2023


Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments


Traws Pharma Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings Call Transcript: Q2 2023


Traws Pharma Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Quarterly report: Q2 2023


Traws Pharma Earnings release: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings release: Q2 2023


Traws Pharma Proxy statement: Proxy Filing

Jul 21, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Proxy statement: Proxy Filing


Traws Pharma Registration statement: Registration Filing

Jun 30, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Registration statement: Registration Filing


Traws Pharma Proxy statement: Proxy Filing

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Traws Pharma Proxy statement: Proxy Filing


Dwarn2021
Dwarn2021 Jun. 24 at 7:56 PM
$TRAW Interesting: https://srnnews.com/exclusive-trump-to-seek-more-than-1-4-billion-in-ebola-funding-from-congress/
1 · Reply
Boywithathorn
Boywithathorn Jun. 24 at 5:35 PM
$TRAW painful hold. Inept management. So what’s the deal with the fda hold on the influenza drug? Why not concentrate on getting that hold lifted rather than 2nd rate UK office? Though my average is 90 cents I’m not sure if these old facks have a clue at this company.
0 · Reply
Boywithathorn
Boywithathorn Jun. 23 at 9:56 PM
$TRAW good job shorts. Staying strong. We need you to bust though $1. It’s coming.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 23 at 8:32 PM
Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand https://ow.ly/Gc0Q50Zg1CJ Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors. $TRAW
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 23 at 4:18 PM
$TRAW 1 dollar incoming!!
0 · Reply
Boywithathorn
Boywithathorn Jun. 23 at 3:48 PM
$TRAW $TRAW wish it would flag and try to overtake $1.
0 · Reply
Jbjb90
Jbjb90 Jun. 23 at 2:21 PM
$TRAW starting to get more expensive to short again
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 22 at 8:25 PM
$TRAW shorts in trouble if they don't cover by end of the month, Q3 is only a few days away....
0 · Reply
Boywithathorn
Boywithathorn Jun. 22 at 7:50 PM
$TRAW Shorts are going to have to cover soon. Price will get back to normalcy. Prob $1.30-$1.50. They are not giving up on their drug but just putting together a better toxicology report. With doing so most likey will fix the issue. This keeps the 50 million warrants on base as well.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 22 at 7:38 PM
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program https://ow.ly/gzWJ50ZfpR8 Traws Pharma, Inc.'s ( $TRAW ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 22 at 7:36 PM
$TRAW this is not staying this low much longer, shorts pressed their luck....
0 · Reply
Boywithathorn
Boywithathorn Jun. 22 at 7:30 PM
$TRAW $1+ shortly.
0 · Reply
Jbjb90
Jbjb90 Jun. 22 at 7:17 PM
$TRAW beautiful rally towards close again 💪
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 22 at 2:04 PM
BUY BIOTECH STOCKS AND STOP CRYING. LAST YEAR THE BIOTECH MARKET MADE 80% IN RETURN TO CAPITAL!! $OTLK $NRSN $CGEN $COCH $TRAW
0 · Reply
Jbjb90
Jbjb90 Jun. 22 at 12:05 PM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-provides-updated-guidance-on-influenza-prophylaxis-bo28tlfmvs7t.html
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 22 at 12:02 PM
$TRAW Traws Pharma (TRAW) plans Q3 2026 MHRA resubmission for Phase 2a flu study. Traws Pharma, Inc. is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company expects to resubmit this package in the third quarter of 2026 to allow a planned Phase 2a human influenza challenge study in healthy volunteers to proceed. Management believes the study could provide important proof-of-concept data for tivoxavir marboxil as an oral prophylaxis for seasonal influenza. Traws notes that tivoxavir marboxil has shown broad in vitro activity across multiple seasonal influenza strains and a pharmacokinetic profile consistent with chemoprophylactic use, and it plans to profile additional molecules in its influenza treatment program. https://www.stocktitan.net/sec-filings/TRAW/8-k-traws-pharma-inc-reports-material-event-356a4809061a.html
0 · Reply
focafoca99
focafoca99 Jun. 22 at 11:10 AM
$TRAW plans to resubmit an updated data package to the UK regulator for its tivoxavir marboxil testing. https://www.rapidticker.com/news/traw-sec-filing-1f878e
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 22 at 7:56 AM
$TRAW insiders keep buying shares. no selling. Institutions own approximately 44% to 52% of Traws Pharma, Inc. (NASDAQ: TRAW), holding between 4.4 million and 8.6 million shares of common stock.
1 · Reply
KoalaFlipper
KoalaFlipper Jun. 22 at 7:51 AM
$TRAW latest news https://www.streetwisereports.com/article/2026/06/20/traws-pharma-positions-long-acting-antivirals-for-influenza-and-outbreak-threats-as-sector-opportunities-expand.html
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 20 at 9:14 PM
This coming week might be a good time for biotech stocks!! The coming week is shaping up to be massive for the biotech sector due to a flurry of major clinical data readouts, key FDA decisions, and the kickoff of the industry's premier global partnering event. The BIO International Convention: Running June 22–25 in San Diego, this is the largest biotechnology event globally. It regularly drives high levels of M&A activity, licensing deals, and early-stage capital inflows. You can check the conference program or track participating companies on the High M&A and Buyout Pressures: Large-cap pharmaceutical companies are under significant pressure to replenish their pipelines ahead of major patent expirations. With significant cash on hand, they are actively acquiring clinical-stage assets. High-profile recent acquisitions, like Biogen's buyout of RayThera, highlight this trend. $CGEN $OTLK $NRSN $TRAW $COCH
3 · Reply
Extorsions
Extorsions Jun. 18 at 9:00 PM
$TRAW not realizing this is just ontx which was a scam company that lied about their phase 2 pipeline trial data and then the board sold off mass amounts of shares before it collapsed 99 percent the next day. Lol
1 · Reply
AllmightyDollah
AllmightyDollah Jun. 18 at 8:45 PM
$TRAW if this was management or a fund buying I guess that’s cool. Guess we will see Monday. Over 400k shares last minutes of trading day.
2 · Reply